NC
GBT

Nehal Chopra’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Nehal Chopra’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-35,000
Closed -$1.93M – 131
2020
Q3 		$1.93M Buy
+35,000
New +$2.22M 0.28% 72

Other funds holding GBT

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Nehal Chopra's GBT Position: Q4 2020 in Review

Nehal Chopra sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2020, closing a stake of 35,000 shares — an estimated $1.93M sold.

Nehal Chopra first reported a position in GBT in Q3 2020 and held it in 1 quarter. The position peaked at $1.93M in Q3 2020. 228 funds tracked by Wall St. Rank hold GBT as of Q4 2020.

  • Nehal Chopra reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Nehal Chopra sold 35,000 Global Blood Therapeutics, Inc. shares in Q4 2020, an estimated $1.93M.
  • Nehal Chopra first reported a position in Global Blood Therapeutics, Inc. in Q3 2020 and held it in 1 quarter.
  • Nehal Chopra's Global Blood Therapeutics, Inc. position peaked at $1.93M in Q3 2020.
  • 228 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2020.

Based on Ratan Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.